SCHEMBL6405789

SCHEMBL6405789

CCCN(CCC)Cc1cccc([C]=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ HRH3 Q9Y5N1 1/20 0.47
▸ BCHE P06276 6/20 0.47
▸ DRD2 P14416 2/20 0.42
▸ DRD3 P35462 2/20 0.42
▸ DRD1 P21728 1/20 0.42
▸ DRD4 P21917 1/20 0.42
▸ DRD5 P21918 1/20 0.42
▸ MEP1A Q16819 1/20 0.42
▸ MEP1B Q16820 1/20 0.42
▸ PTGES O14684 1/20 0.41
▸ GRIN2D O15399 1/20 0.41
▸ GRIN3B O60391 1/20 0.41
▸ GRIN1 Q05586 1/20 0.41
▸ GRIN2A Q12879 1/20 0.41
▸ GRIN2B Q13224 1/20 0.41
▸ GRIN2C Q14957 1/20 0.41
▸ GRIN3A Q8TCU5 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6406759 0.88 CYP1A2 (0.45) TSHRHRH3BCHEMEP1AMEP1B
SCHEMBL6406480 0.80 ALDH1A1 (0.48) TSHRHRH3MEP1AMEP1BPTGES
SCHEMBL28764949 0.79 MEP1A (0.56) TSHRHSD17B10HRH3BCHEDRD2
SCHEMBL910177 0.78 DRD2 (0.40) DRD2DRD3DRD1DRD4DRD5
SCHEMBL6409478 0.78 HRH3 (0.64) HRH3BCHECYP1A2CYP2D6CYP2C9
SCHEMBL13818587 0.78 HRH3 (0.53) TSHRHSD17B10HRH3BCHEDRD2
SCHEMBL7423782 0.77 TRPA1 (0.42) TSHRMEP1AMEP1BPTGESCYP1A2
SCHEMBL910601 0.77 MGLL (0.43) CYP1A2
SCHEMBL13818690 0.77 DRD2 (0.54) TSHRHSD17B10HRH3BCHEDRD2
SCHEMBL13775217 0.77 HRH3 (0.52) TSHRHSD17B10HRH3BCHEDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222098-A1 Regulation of meiosis NOVO NORDISK A/S (DK) 2005-10-06 — — US disclosed
EP-0767798-B1 STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS NOVO NORDISK AS (DK) 2003-09-03 — — EP disclosed
US-20030004148-A1 Regulation of meiosis NOVO NORDISK A/S (DK) 2003-01-02 — — US disclosed
EP-0767798-A1 STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS NOVO NORDISK A/S (DK) 1997-04-16 — — EP disclosed
WO-1996000235-A1 STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS NOVO NORDISK A/S (DK) 1996-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222098-A1 Regulation of meiosis ALPG, MNS1, BUB1B TSHR 4376/4885HSD17B10 1314/4885HRH3 3595/4885
US-20030004148-A1 Regulation of meiosis ALPG, MNS1, BUB1B TSHR 4376/4885HSD17B10 1314/4885HRH3 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback